![1610758-20-7 | O-(2-Ethylbutyl) Dabigatran Ethyl Ester | N-[[2-[[[4-[[[(2-Ethylbutoxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-Alanine Ethyl Ester; Dabigatran Impurity C | C₃₇H₃₈N₇O₅ | TRC 1610758-20-7 | O-(2-Ethylbutyl) Dabigatran Ethyl Ester | N-[[2-[[[4-[[[(2-Ethylbutoxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-Alanine Ethyl Ester; Dabigatran Impurity C | C₃₇H₃₈N₇O₅ | TRC](https://www.trc-canada.com/prod-img/E900655.png)
1610758-20-7 | O-(2-Ethylbutyl) Dabigatran Ethyl Ester | N-[[2-[[[4-[[[(2-Ethylbutoxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-Alanine Ethyl Ester; Dabigatran Impurity C | C₃₇H₃₈N₇O₅ | TRC
![Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation - Zachary Stacy, Sara Richter, 2017 Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation - Zachary Stacy, Sara Richter, 2017](https://journals.sagepub.com/cms/10.1177/1076029616634886/asset/images/large/10.1177_1076029616634886-fig1.jpeg)